Van der Elst K, Verschueren P, Stouten V, et al. - In this prospective, 2-year, investigator-initiated, randomized controlled trial rooted in daily practice and implementing the treat-to-target principle, experts reported the impact of an approach of rapid and persistent disease control and not treatment type on patient-reported outcomes and investigated the contribution of rapid and persistent disease control to well-being following 1 year of treatment. In total, 333 people were available for the main analyses, comprising 140 early persistent responders. At year 1, rapid and persistent disease control and not treatment type were related to favorable patient-reported health and illness perceptions, however, baseline psychosocial variables were most significant. Thus, data symbolize possibilities to expand the scope of the treat-to-target principle in early RA.